Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
27
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Measurement of tamsulosin in human serum by liquid chromatography–tandem mass spectrometry

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Highlights

          • A method to quantify tamsulosin by liquid chromatography–tandem mass spectrometry.

          • Simple extraction method from serum, excellent recovery, linear range 0.2–50 ng/mL.

          • In-house synthesis of internal standard, d9-finasteride.

          • Validated method with acceptable reproducibility, precision, accuracy and stability.

          • Useful to assess compliance and pharmacokinetics in studies of benign prostatic hyperplasia.

          Abstract

          A simple, sensitive and robust method to extract tamsulosin from human serum, and quantify by liquid chromatography–tandem mass spectrometry (LC–MS/MS) was developed and validated and is applicable as a measure of compliance in clinical research. Tamsulosin was extracted from human serum (100 μL) via liquid–liquid extraction with methyl tert-butyl ether (2 mL) following dilution with 0.1 M ammonium hydroxide (100 μL), achieving 99.9% analyte recovery. Internal standard, d9-finasteride, was synthesised in-house. Analyte and internal standard were separated on an Ascentis ® Express C18 (100 mm × 3 mm, 2.7 μm) column using a gradient elution with mobile phases methanol and 2 mM aqueous ammonium acetate (5:95, v/v). Total run-time was 6 min. Tamsulosin was quantified using a triple quadrupole mass spectrometer operated in multi-reaction-monitoring (MRM) mode using positive electrospray ionisation. Mass transitions monitored for quantitation were: tamsulosin m/ z 409 → 228 and d9-finasteride m/ z 382 → 318, with the structural formulae of ions confirmed by Fourier transform ion cyclotron resonance mass spectrometry (within 10 ppm). The limit of quantitation was 0.2 ng/mL, and the method was validated in the linear range 0.2–50 ng/mL with acceptable inter- and intra-assay precision and accuracy and stability suitable for routine laboratory practice. The method was successfully applied to samples taken from research volunteers in a clinical study of benign prostatic hyperplasia.

          Related collections

          Most cited references17

          • Record: found
          • Abstract: not found
          • Article: not found

          Benign prostatic hyperplasia. Part 1--diagnosis.

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Alpha blockers for the treatment of benign prostatic hyperplasia.

            The evolution of alpha blocker therapy for benign prostatic hyperplasia (BPH) has focused on improving convenience and tolerability. Indications for treating BPH include reversing signs and symptoms or preventing progression of the disease. The indication that most commonly drives the need for intervention is relief of lower urinary tract symptoms (LUTS) with the intent of improving quality of life. Alpha blockers are the most effective, least costly, and best tolerated of the drugs for relieving LUTS. Four long-acting alpha 1 blockers are approved by the Food and Drug Administration for treatment of symptomatic LUTS/BPH: terazosin, doxazosin, tamsulosin, and alfuzosin. All are well tolerated and have comparable dose-dependent effectiveness. Tamsulosin and alfuzosin SR do not require dose titration. Alfuzosin, terazosin, and doxazosin have all been shown to be effective in relieving LUTS/BPH independent of prostate size.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Isocratic and gradient elution chromatography: a comparison in terms of speed, retention reproducibility and quantitation.

              Chromatographers are cautioned to avoid gradient elution when isocratic elution will do. In this work, we compared the analytical properties of gradient and isocratic separations of a sample which can be done quite readily under isocratic conditions. We found that gradient elution gave a shorter overall analysis with similar resolution of the critical pair compared to isocratic elution without sacrificing repeatability in retention time, peak area and peak height or linearity of the calibration curve. We also obtained acceptable repeatability in peak area/height and linearity of calibrations curves for a sample that required gradient elution using a practical baseline subtraction technique. Based on these results and related work which show that columns can be reequilibrated by flushing with less than two column volumes of the initial eluent, we conclude that many of the reasons given to avoid gradient elution deserve serious reconsideration, especially for those samples which are easily separated isocratically. However, we believe isocratic elution will remain preferable when: (1) the sample contains less than 10 weakly retained components (i.e. the last peak elutes with k' < 5) or (2) the gradient baseline impedes trace analysis.
                Bookmark

                Author and article information

                Contributors
                Journal
                J Chromatogr B Analyt Technol Biomed Life Sci
                J. Chromatogr. B Analyt. Technol. Biomed. Life Sci
                Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
                Elsevier
                1570-0232
                1873-376X
                01 July 2013
                01 July 2013
                : 930
                : 100
                : 121-128
                Affiliations
                [0005]Endocrinology, University/British Heart Foundation Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, 47, Little France Crescent, Edinburgh EH16 4TJ, United Kingdom
                [0010]Mass Spectrometry Core, Wellcome Trust Clinical Research Facility, Queen's Medical Research Institute, University of Edinburgh, 47, Little France Crescent, Edinburgh EH16 4TJ, United Kingdom
                [0015]Urology, NHS Lothian, Western General Hospital, Crewe Road South, Edinburgh EH4 2XU, United Kingdom
                Author notes
                [* ]Corresponding author at: Endocrinology, University/British Heart Foundation Centre for Cardiovascular Science, Queen's Medical Research Institute, University of Edinburgh, 47, Little France Crescent, Edinburgh EH16 4TJ, United Kingdom. Tel.: +44 131 242 6763; fax: +44 131 242 6779. ruth.andrew@ 123456ed.ac.uk
                Article
                CHROMB18372
                10.1016/j.jchromb.2013.04.020
                3682175
                23743242
                ce5158bb-b7f0-471c-b8cb-44477d5f992e
                © 2013 The Authors

                This document may be redistributed and reused, subject to certain conditions.

                History
                : 26 September 2012
                : 14 April 2013
                Categories
                Article

                Analytical chemistry
                bph, benign prostatic hyperplasia,tamsulosin,finasteride,liquid chromatography,mass spectrometry,serum,prostate

                Comments

                Comment on this article